|
Market Closed -
Nasdaq Stockholm
17:00:00 15/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 5.900 SEK | -2.64% |
|
-17.02% | -80.40% |
| 09:57am | 14 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange | FW |
| 10-14 | Orexo reports promising results for oral semaglutide tablet | FW |
Company Valuation: Orexo AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 1,715 | 1,184 | 648.2 | 532.1 | 603.8 | 1,039 |
| Change | - | -30.93% | -45.27% | -17.9% | 13.47% | 72% |
| Enterprise Value (EV) 1 | 1,500 | 1,231 | 836 | 834.9 | 956.5 | 617.7 |
| Change | - | -17.98% | -32.07% | -0.12% | 14.56% | -35.42% |
| P/E | -20.4x | -5.3x | -3.65x | -4.14x | -2.97x | 1.63x |
| PBR | 3.07x | 3.39x | 3.34x | 9.04x | -4.78x | 2.13x |
| PEG | - | -0x | 0.2x | 0.1x | -0.1x | -0x |
| Capitalization / Revenue | 2.58x | 2.1x | 1.04x | 0.83x | 1.02x | 39.9x |
| EV / Revenue | 2.26x | 2.18x | 1.34x | 1.31x | 1.62x | 23.8x |
| EV / EBITDA | 246x | -6.95x | -11.3x | 309x | 73.6x | -2.09x |
| EV / EBIT | -85.7x | -5.65x | -7.33x | -18.6x | -6.55x | -1.81x |
| EV / FCF | -7.72x | -7.06x | -14.1x | -38.9x | 191x | -33.2x |
| FCF Yield | -13% | -14.2% | -7.1% | -2.57% | 0.52% | -3.01% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -2.454 | -6.512 | -5.17 | -3.73 | -5.89 | 18.46 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 663.6 | 565 | 624.3 | 638.8 | 590 | 26 |
| EBITDA 1 | 6.1 | -177.2 | -73.9 | 2.7 | 13 | -295.6 |
| EBIT 1 | -17.5 | -218 | -114 | -44.8 | -146.1 | -340.6 |
| Net income 1 | -84.4 | -223.5 | -177.6 | -128.3 | -203 | 639.3 |
| Net Debt 1 | -214.3 | 46.4 | 187.8 | 302.8 | 352.7 | -420.9 |
| Reference price 2 | 50.000 | 34.500 | 18.860 | 15.460 | 17.500 | 30.100 |
| Nbr of stocks (in thousands) | 34,295 | 34,328 | 34,368 | 34,421 | 34,505 | 34,505 |
| Announcement Date | 23/03/21 | 31/03/22 | 28/03/23 | 28/03/24 | 28/03/25 | 27/03/26 |
1SEK in Million2SEK
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 22.24M | |
| 34.58x | 12.46x | 26.12x | 0.57% | 1,077B | |
| 37.53x | 6.26x | 17.55x | 2.1% | 612B | |
| 36.12x | 8.31x | 17.13x | 2.45% | 501B | |
| 113.84x | 6x | 25.7x | 2.32% | 364B | |
| 20.01x | 4.88x | 12.13x | 2.7% | 353B | |
| 20.46x | 5.37x | 13.21x | 2.96% | 278B | |
| 21.15x | 4.27x | 12.26x | 2.07% | 251B | |
| 27.06x | 6.97x | 12.48x | 2.37% | 230B | |
| -44.86x | 6.85x | 26.64x | 2.14% | 190B | |
| Average | 29.54x | 6.82x | 18.14x | 2.19% | 385.65B | |
| Weighted average by Cap. | 35.12x | 7.99x | 19.65x | 1.87% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ORX Stock
- Valuation Orexo AB
Select your edition
All financial news and data tailored to specific country editions
